Wellcome Leap – Cutting Alzheimer's Risk through Endocrinology (CARE)
Event details
| Date | 14.03.2025 |
| Category | Call for proposal |
Aim: The Wellcome Leap Program, established by Wellcome, aims to deliver breakthroughs in human health by providing funding at scale and within short timeframes. Wellcome Leap's eleventh funding initiative is Cutting Alzheimer's Risk through Endocrinology (CARE), which seeks to address the risk of Alzheimer's among women.
CARE aims to cut the lifetime risk of Alzheimer's among women by half, reducing risk for 330 million women around the world. Female-specific risks remain unquantified in available population-attributable risk (PAR) models. These gaps highlight the need for a deeper comprehension of Alzheimer's mechanisms linked to: sex-specific biology; robust, sex-specific risk biomarkers; and tailored interventions to support cognitive function and prevent neurodegeneration in women.
Proposals are required to focus on one or more of the following Thrust Areas and proposers should clearly relate work in these areas to one or more of the programme goals.
Duration: 3 years
Eligibility: Wellcome Leap accepts project proposals from any legal entity, based in any legal jurisdiction, including academic, non-profit, for-profit, and regulatory/professional organizations.
How to Apply: Applicants should follow the guidelines (here) and use the abstract template (here), and upload their proposal on the application portal which will open on 7 March.
Deadline: Abstracts due 14 March 2025
Further information
CARE aims to cut the lifetime risk of Alzheimer's among women by half, reducing risk for 330 million women around the world. Female-specific risks remain unquantified in available population-attributable risk (PAR) models. These gaps highlight the need for a deeper comprehension of Alzheimer's mechanisms linked to: sex-specific biology; robust, sex-specific risk biomarkers; and tailored interventions to support cognitive function and prevent neurodegeneration in women.
Proposals are required to focus on one or more of the following Thrust Areas and proposers should clearly relate work in these areas to one or more of the programme goals.
- Thrust Area 1: Identify high-precision female-specific neuroendocrine targets and therapies for Alzheimer's risk reduction.
- Thrust Area 2: Develop high-affinity in vivo brain imaging probes for neuroendocrine function in clinical populations and their potential therapeutic application.
- Thrust Area 3: Development of predictive models that halve Alzheimer's risk in women and their deployment as risk assessment tools for clinical use
Duration: 3 years
Eligibility: Wellcome Leap accepts project proposals from any legal entity, based in any legal jurisdiction, including academic, non-profit, for-profit, and regulatory/professional organizations.
How to Apply: Applicants should follow the guidelines (here) and use the abstract template (here), and upload their proposal on the application portal which will open on 7 March.
Deadline: Abstracts due 14 March 2025
Further information
- More information about the program is available here and the full program description is available here.
- The application portal can be found will open on 7 March here
- For any other questions, please contact the Research Office.
Practical information
- General public
- Free